Jan 2020 – https://www.nice.org.uk/guidance/ng151
1.1 The following are recommended as options for the adjuvant treatment of patients with stage III (Dukes’ C) colon cancer following surgery for the condition:
* capecitabine as monotherapy
* oxaliplatin in combination with 5-fluorouracil and folinic acid.
1.2 The choice of adjuvant treatment should be made jointly by the individual and the clinicians responsible for treatment. The decision should be made after an informed discussion between the clinicians and the patient; this discussion should take into account contraindications and the side-effect profile of the agent(s) and the method of administration as well as the clinical condition and preferences of the individual.
NICE TA 100
Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
Irinotecan and oxaliplatin, within their licensed indications, are recommended
as treatment options for people with advanced colorectal cancer as follows:
* irinotecan in combination with 5-fluorouracil and folinic acid as first-line
therapy, or irinotecan alone in subsequent therapy
* oxaliplatin in combination with 5-fluorouracil and folinic acid as first-line or
NICE TA 93
Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer AUG 2005